FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:965 March 1, 2007 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Campbell, E. G. PubMed Citation

To the Editor: Campbell et al. (Nov. 30 issue)¹ provide valuable data on financial conflicts of interest of members of institutional review boards (IRBs). However, they do not address potentially more problematic conflicts of interest inherent in the IRB system. Industry-sponsored protocols are reviewed and approved by IRBs consisting almost entirely of employees of the academic medical center, many of whom may be involved in the conduct of industry-sponsored research. Disapproval of such protocols means that less money will flow into the institution and its clinical-trials operation, with a potential deleterious financial effect. Consider, for example, a placebo-controlled trial evaluating . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.